The potential risk window for any possible causal link between etanercept and cancer is unknown, but 5 cases had only received etanercept for 6 months or less prior to their cancer diagnoses. contention. What is clear MK-2 Inhibitor III is that there is much that is currently unfamiliar to be able to convincingly demonstrate a substantial risk of cancer in children with juvenile idiopathic arthritis treated with etanercept. Conversely, there is ample evidence demonstrating remarkable benefit of etanercept in treating juvenile idiopathic arthritis. Physicians treating child years arthritis should weigh these potential risks and benefits with patients and their families discussing the current limitations in available data regarding the risk of cancer in children treated with etanercept for juvenile idiopathic arthritis. == Introduction == The bench to bedside transition of tumor necrosis factor (TNF) inhibitors has been a truly remarkable breakthrough in the treatment of both adult and pediatric chronic inflammatory arthritis, and no less deserving than awarding the 2003 Lasker Clinical Medical Research Award to Drs. Feldman and Maini [1]. The first of these wonder drugs to be approved by the Food and Drug Administration (FDA) and used extensively Rabbit polyclonal to IL7 alpha Receptor to treat juvenile idiopathic arthritis (JIA) was the TNF receptor2-imumoglobulin Fc tail fusion protein, etanercept [2]. In clinical trials, etanercept has been shown to be safe and highly efficacious in treating JIA [3]. However, in November 2009, the FDA placed a MK-2 Inhibitor III new black box warning on TNF inhibitors, including etanercept, warning of the risks of malignancy. This was the result of the FDA identifying 48 cases of malignancy occurring in children associated with the use of the TNF inhibitors, infliximab (31 cases), adalimumab (2 cases), and etanercept (15 cases) [4]. The authors of this statement estimated that this rate of overall malignancy associated with etanercept was approximately equal to the background rate in the general population, but the rate of lymphoma was approximately 5 times the background rate. Recently, MK-2 Inhibitor III employees of Amgen (makers of etanercept) and colleagues reported in this journal that MK-2 Inhibitor III there does not appear to be an overall increased risk of malignancy associated with etanercept but there may be an increased risk for lymphoma [5]. == Conversation == McCroskery and colleagues recognized 18 malignancies worldwide among children who received etanercept, and 3 of these remain unconfirmed [5]. The potential risk window for any possible causal link between etanercept and cancer is unfamiliar, but 5 cases had only received etanercept for 6 months or less prior to their cancer diagnoses. An even bigger question remains as to what proportion of the risk of cancer in patients with JIA is usually attributable to treatment with etanercept. Prior or concurrent treatment with certain non-biologic medications, such as methotrexate (which was received by 13 of the cases), may carry their own risks of lymphoma development in children [6] and adults [7] with chronic inflammatory arthritis. Very recent impartial preliminary studies have suggested that biologic nave JIA patients experience an approximately 2- to 3-fold increased risk of cancer [8,9], and a nearly 4-fold increased risk of lymphoproliferative cancers [9]. This is much like adults with rheumatoid arthritis where the disease itself confers a risk of lymphoma development [10]. Some recent large population studies have shown no additional risk of lymphoma conferred by TNF inhibitors in RA patients [11,12]. Thus, it.